Company intelligence / Profile preview
AIM ImmunoTech
Ocala, Florida, United Statesaimimmuno.com ↗
- Ownership
- Public · AIM
- Development stage
- Phase 2
01
Overview
AIM ImmunoTech’s lead program Ampligen® has shown broad-spectrum activity as an immune modulator. It has demonstrated positive preliminary data in pancreatic cancer trials and favorable results in a Phase 2 study of post-COVID fatigue. The company continues to expand its pipeline with ongoing or planned studies in various solid tumors and viral diseases. Several programs are supported by partnerships with major pharma companies like AstraZeneca and Merck as well as the National Cancer Institute. Ampligen® is approved for severe CFS in Argentina.
- Therapeutic areas
- OncologyNeurologyInfectious Diseases
- Modalities
- RNA-based drugs (e.g., double-stranded RNA)immunomodulatorsnatural interferon
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
AstraZeneca (for Imfinzi combination studies)MerckNational Cancer Institute funding support for certain trialsAmarex Clinical Research as CRO partner for clinical trial management
04
Financials
- Market cap
- $6.1M
- Total revenue
- $88K
- Enterprise value
- $25K
Beyond the preview
Go deeper on AIM ImmunoTech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIM ImmunoTech.